MENU CONTENTS

Financial info

  • Market : Korea
  • Symbol : 078160
  • ISIN : KR7078160009
  • Industry : Pharmaceuticals

CONPANY PRESENTATION

MEDIPOST is a leading stem cell biotechology company focused on developing products to meet unmet
medical needs such as those related to regenerative or functional recovery of knee articular cartilage, the
nervous system, the pulmonary system and hematopoietic transplantation engraftment areas.
MEDIPOST provides services and develops products related to a readily available and non-controversial
source - human umbilical cord blood and human umbilical cord blood derived mesenchymal stem cells
(hUCB-MSCs), respectively.
The stem cells, coming from unrelated healthy donors, have demostrated the
ability to regenerate and/or to recover functionality of different types of damaged tissues.
Such adult stem cell therapies having an "off-the-self"concept revolutionize medical treatments and bring about a new era of mass-manufactured allogeneic stem cell drug products.

Sales

매출액 그래프 이미지

Operating Income

영업이익 그래프 이미지

Equity Capital

자기자본 그래프 이미지

Key Figures

  2014 2015 2016
Yearly Income Statement (KRW mn)
Sales 29,715 35,089 28,654
Cord blood bank 22,077 23,971 15,885
Stem cell therapy 2,793 4,125 5,638
Nutritional supplements 4,048 4,201 4,251
Others 797 2,792 2,880
Operating Income -388 1,152 -8,550
Net Income -349 3,490 -4,284
Summarized Financial Statements (KRW mn)
Total Liabilities 62,348 36,440 35,815
Equity Capital 120,206 150,166 147,916
R&D Investment (KRW mn)
R&D Investment 10,529 9,919 16,638
R&D /Sales (%) 35% 28% 58%
Contact Investor Relations
Tel.: +822-3465-6615
Fax: +822-3465-6688
E-mail: ir@medi-post.co.kr
ADD 21, Daewangpangyo-ro 644 (Sampyeong- dong), Bundang-gu, Seongnam-si, Gyeonggi-do, Korea
www.medi-post.com

상단으로